Verily Watch Cardio (AF and ECG) Study

Atrial Fibrillation Clinical Trial

Official title:

Verily Watch Cardio (AF and ECG) Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT06041373
• Other study ID #: 104343
• Status: Withdrawn
• Start date: November 2023
• Est. completion date: November 2024

Study information

• Verified date: December 2023
• Source: Verily Life Sciences LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is designed to evaluate the performance of the Verily Watch Cardio for recording electrocardiogram (ECG) and photoplethysmography (PPG) signals and detecting suspected atrial fibrillation (AF) episodes, in a free-living environment, in participants at risk for having an AF event.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2024
• Est. primary completion date: July 2024
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

• At least 22 years old

• Able to read and speak English

• Participant understands the study requirements and is able and willing to sign written Informed Consent

• At risk of having an AF event, as determined by having a diagnosis of paroxysmal AF (PAF) and meeting one or more of the following:

1. Scheduled or to be scheduled to undergo AF ablation

2. AF burden of =25% in the 3 months prior to consent date as confirmed via an implantable loop recorder (ILR), holter monitor, or adhesive monitoring patch

3. CHA2DS2VASc score =3

4. Left atrial diameter =4.4 cm as confirmed by transthoracic echo (TTE) within one year of consent

• Without significant limitation in ability to participate in the study, in the opinion of the Investigator

Exclusion Criteria:

• Have a pacemaker or implantable cardioverter defibrillator (ICD)

• Currently on class Ic or class III antiarrhythmic medication that has been successful in eliminating AF (no documented AF of more than 30 seconds since the initiation of the medication). Should be at least one week off medication.

• Had successful AF ablation (no documented AF of more than 30 seconds post procedure)

• Known severe allergy to nickel or metal jewelry

• Known allergic reaction to polyester, nylon, spandex, adhesives or hydrogels; or with family history of adhesive skin allergies

• Are diagnosed with persistent AF

• Have an implantable neuro-stimulator

• Currently wearing an ECG patch that prevents the use of the FDA-cleared wearable ECG patch, at the discretion of the Investigator.

• Have discolored wrists (e.g., tattoos, ink), at the discretion of the Investigator.

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Device:
• Verily Watch Cardio
The Verily Watch Cardio is an investigational wrist-worn wearable device containing multiple sensors to measure physiological and environmental metrics, including electrodes that enable a single-lead electrocardiogram (ECG) measurement and a photoplethysmogram (PPG) sensor to monitor for irregular pulses.
• iRhythm Zio monitor
The iRhythm Zio monitor, the reference device, is an FDA-cleared single-patient use, continuously recording ECG monitor that can be worn for up to 14 days.
• Schiller CARDIOVIT FT-1
The Schiller CARDIOVIT FT-1, the reference device, is an FDA-cleared portable 12-lead ECG machine capable of recording continuous standard 12-lead resting ECG for up to 4 minutes.

Locations

Country	Name	City	State
United States	Colorado Heart and Vascular	Lakewood	Colorado
United States	Ascension Providence Hospital	Southfield	Michigan
United States	Wake Forest Medical Center	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Verily Life Sciences LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity and Specificity of suspected AF episode detection	Sensitivity and Specificity of suspected AF episode detection by the irregular pulse detection algorithm	Up to 14 days
Secondary	A sensitivity analysis estimating the range of sensitivities and specificities	A sensitivity analysis estimating the range of sensitivities and specificities observed when imputing missing test device data	Up to 14 days
Secondary	Sensitivity and Specificity in defined subgroups	Sensitivity and Specificity in subgroups defined by: race, age-groups, activity level, skin-tone and AF-burden	Up to 14 days
Secondary	Mean difference in Interbeat interval (IBI) and the associated limits of agreement (LoA)	Mean difference in Interbeat interval (IBI) and the associated limits of agreement (LoA) based on recorded ECG data	Up to 14 days
Secondary	Participant-level and heartbeat level sensitivity/specificity of P-wave detection	Participant-level and heartbeat level sensitivity/specificity of P-wave detection based on recorded ECG data	Up to 14 days